Pharmaceuticals: Boehringer CEO on the potential of the pharmaceutical industry: The West has "no monopoly on innovation"
Chinese companies are rapidly catching up in the development of new medicines. Shashank Deshpande, CEO of Boehringer Ingelheim, sees this as an incentive for Europe.
Boehringer Ingelheim CEO Shashank Deshpande views growing competition from China as an incentive for the industry, citing that Europe and America do not have a monopoly on innovation. He made these comments at the Asia-Pacific conference of the German economy in Seoul, where he also highlighted the region's increasing importance for pharmaceutical innovations.
Boehringer Ingelheim is conducting over 200 clinical trials in the region, excluding China, and collaborating with around 160 scientific institutions. The company is also exploring the use of artificial intelligence in pharmaceutical research, having recently partnered with Microsoft to accelerate clinical trials. Chancellor Friedrich Merz opened the conference, which drew around 1000 economic representatives from Germany and the Indo-Pacific region.
Written by urgent.news from Handelsblatt's report — not a translation of it. Machine-written — may contain errors; check the original before relying on it.
